Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2001 Summer;7(2):199-213.
doi: 10.1111/j.1527-3458.2001.tb00195.x.

Ondansetron: a selective 5-HT(3) receptor antagonist and its applications in CNS-related disorders

J H Ye  1 , R Ponnudurai, R Schaefer
Affiliations
Review

Ondansetron: a selective 5-HT(3) receptor antagonist and its applications in CNS-related disorders

J H Ye et al. CNS Drug Rev. 2001 Summer.

Abstract

Ondansetron is a selective 5-hydroxytryptamine(3) (5-HT(3)) receptor antagonist that has been introduced to clinical practice as an antiemetic for cancer treatment-induced and anesthesia-related nausea and vomiting. Its use under these circumstances is both prophylactic and therapeutic. It has a superior efficacy, safety and pharmacoeconomic profile compared with other groups of antiemetics, namely antidopaminergics, antihistamines and anticholinergics. However, its place in the management of anticipatory and delayed vomiting in cancer treatment and as a rescue antiemetic in surgical patients needs to be further explored. Furthermore, recent animal and human research also reflects its possible novel application in the treatment of other disease states, such as alcoholism, cocaine addiction, opioid withdrawal syndrome, anxiety disorders, gastrointestinal motility disorders, Tourette's syndrome and pruritus. This review revisits the widespread physiological and pathological effects of 5-HT and discusses both the basic science literature and the clinical developments responsible for the conventional and novel uses of ondansetron. In addition, new discoveries relating to the effects of ondansetron on other receptors/channels and their possible therapeutic applications are presented.

PubMed Disclaimer

References

    1. Andrews PLR, Bailey HE, Hawthorn J, Stables R, Tyers MB. GR38032F, a novel 5‐HT3‐receptor antagonist, can both abolish emesis induced by cyclophosphamide or radiation in the ferret. Br J Pharmacol 1987;91(Suppl): 417P.
    1. Andrews PRL, Davis CJ. The mechanism of emesis induced by anticancer therapies In: Andrews PRL, ed. Emesis in anticancer therapy: Mechanisms and treatment. London : Chapman and Hall Medical, 1993:113–161.
    1. Andrews PLR, Hawthorn J. Evidence for an extra‐abdominal site of action for the 5‐HT3‐receptor antagonist BRL24924 in the inhibition of radiation‐evoked emesis in the ferret. Neuropharmacology 1987;26:1367–1370. - PubMed
    1. . Anonymous :ASHP therapeutic guidelines on the pharmacologic management of nausea and vomiting in adult and pediatric patients receiving chemotherapy or radiation therapy or undergoing surgery. Am J Health Syst Pharm 1999;56:729–764. - PubMed
    1. Ashmore SD, Jones CH, Newstead CG, Daly MJ, Chrystyn H. Ondansetron therapy for uremic pruritus in hemodialysis patients. Am J Kidney Dis 2000;35:827–831. - PubMed

Publication types

MeSH terms

LinkOut - more resources